Skip to main
ZYXI
ZYXI logo

Zynex Inc (ZYXI) Stock Forecast & Price Target

Zynex Inc (ZYXI) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 33%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Zynex Inc. reported a 16% year-over-year increase in orders for fiscal year 2024, indicating strong demand for its electrotherapy and pain management medical devices. The company's effective management strategies aim to increase revenue per sales representative to $1 million, further enhancing its financial performance. Additionally, the results from recent clinical studies and the planned expense reduction expected to yield approximately $35 million in annual savings contribute to a positive outlook for Zynex's growth potential and market position.

Bears say

Zynex Inc. is facing significant challenges, as the company has indicated a substantial decline in its expected Q1 2025 sales, projecting at least $30 million, which reflects a 37% year-over-year decrease. Additionally, the fourth-quarter revenue figures showed a 3% year-over-year decline to $46 million, which was notably below expectations, coupled with the trend of decreasing Device sales by 9% year-over-year. The financial outlook for 2025 has been revised downwards significantly to an estimated $140 million, indicating a 28% year-over-year decline, compounded by concerns over operational visibility, competitive pressures, and regulatory hurdles.

Zynex Inc (ZYXI) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 33% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Zynex Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Zynex Inc (ZYXI) Forecast

Analysts have given Zynex Inc (ZYXI) a Buy based on their latest research and market trends.

According to 6 analysts, Zynex Inc (ZYXI) has a Buy consensus rating as of Aug 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Zynex Inc (ZYXI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.